



Florida/Caribbean AIDS Education and Training Center

HIV CareLink

A Newsletter for HIV/AIDS Primary Care Providers

ABOUT US

The Florida/Caribbean AIDS Education and Training Center provides state-of-the-art HIV education, consultation, and resource materials to health care providers in Florida, Puerto Rico and the US Virgin Islands.

Major funding is provided by the US Public Health Service's Health Resources Services Administration (HRSA) DHHS-HAB Grant No. H4AHA00049 through the University of South Florida Center for HIV Education and Research, Michael Knox, PhD, Director.

EDITORS

Jeffrey Beal, MD, AAHIVS (239) 839-4645
aetcbear@embarqmail.com

Joanne J. Orrick, PharmD, AAHIVE (352) 273-7845
orricj@ufl.edu

PEDIATRIC EDITOR

Belinda Beauchamp, MD (787) 281-8501
belinda.beauchamp@upr.edu

MANAGING EDITOR

Kimberly Alfonso, MAcc (813) 974-4430
alfonso@fmhi.usf.edu

Volume 10 - Issue 12

September 1, 2009

Special Bulletin: Opportunistic Infections (OIs) Guidelines for HIV-Exposed and HIV-Infected Children - Updated

Belinda Beauchamp, MD

Clinical Director for PR, Florida/Caribbean AIDS Education and Training Center
Professor in Pediatrics, University of Puerto Rico, School of Medicine

A new updated *Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children* was published by the National Institutes of Health and the Centers for Disease Control and Prevention on August 26, 2009. The report updates and combines into one document earlier versions of guidelines. The guidelines were developed by a panel of specialists in pediatric HIV infection and Infectious diseases from the US government and academic institutions. Clinicians are encouraged to consult the full guidelines at http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf

The new guidelines apply to 23 opportunistic infectious diseases and major changes include:

- Greater emphasis on the importance of ART for preventing and treating OIs (especially for those OIs for which no specific therapy exists)
- Information about the diagnosis and management of immune reconstitution inflammatory syndrome (IRIS)
 - Guidelines emphasize the importance of continuing the ART even though worsening of symptoms
- Information about managing ART in children with OIs, including potentially hazardous drug-drug interactions
- New guidance on diagnosing of HIV infection and presumptively excluding HIV infection in infants that affect the need for initiation of PCP prophylaxis in neonates
 - Infants who have 2 negative tests for HIV (one at ≥ 2 weeks of age and one at ≥ 4 weeks of age), are considered presumptively HIV-uninfected and use of PCP prophylaxis is not necessary

- Updated immunization recommendations for HIV exposed and HIV-infected children including
 - Hepatitis A
 - Human papillomavirus
 - Meningococcal
 - Rotavirus
- Addition of sections on the treatment of:
 - Aspergillosis
 - Bartonella
 - Human Herpes Virus 6, 7, and 8
 - Malaria – this disease may become an OI in HIV-infected immigrant children or HIV-infected children who travel to countries with malaria
 - Progressive multifocal leukodystrophy
- New recommendations on discontinuation of OI prophylaxis after immune reconstitution in children – previously the prophylaxis were given for life but current guidelines provide criteria for discontinuation following immune reconstitution

Save the Date May 14-15, 2010

Florida/Caribbean AETC 19th Annual HIV CONFERENCE

CHOOSE FROM FIVE HIV/AIDS CONCURRENT CLINICAL TRACKS:
Fundamentals • Advanced • Nursing • Pediatrics • En Español

www.FCAETC.org/Conference

SAFETY ALERT: Intelence™ (Etravirine)

Tibotec Therapeutics and FDA issue safety alert for cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme and also hypersensitivity reactions (rash, constitutional symptoms, and sometimes organ dysfunction including hepatic failure). Patients presenting with signs and symptoms of severe skin or hypersensitivity type reactions should immediately stop taking etravirine and seek medical attention.

For more information,
please visit our website:

www.FCAETC.org

To request clinical consultation, please call the
National Clinicians' Consultation Hotline:

1-800-933-3413